Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis
2023
Menooa Ebrahimi | Seyed Arsalan Seyedi | Seyed Ali Nabipoorashrafi | Soghra Rabizadeh | Mojdeh Sarzaeim | Amirhossein Yadegar | Fatemeh Mohammadi | Razman Arabzadeh Bahri | Peyman Pakravan | Paria Shafiekhani | Manouchehr Nakhjavani | Alireza Esteghamati
Abstract Background Lipid accumulation product (LAP) is an index calculated by waist circumference (WC) and triglyceride (TG), which reflects lipid toxicity. This study aims to investigate the association between the LAP index and nonalcoholic fatty liver disease (NAFLD) in a systematic review and meta-analysis. Methods and results PubMed, Scopus, and Web of Science online databases were searched for eligible studies that investigated the association of the LAP index and NAFLD. Sixteen observational studies with 96,101 participants, including four cohort studies, one case‒control study and 11 cross-sectional studies with baseline data, were entered into this analysis. Fourteen studies reported a significant association between the LAP index and NAFLD, and two reported that this relation was not significant; two different meta-analyses (1- mean difference (MD) and 2- bivariate diagnostic test accuracy [DTA]) were conducted using Stata version 14. The LAP index was compared in subjects with and without NAFLD, and the difference was significant with 34.90 units (CI 95: 30.59–39.31, P < 0.001) of the LAP index. The DTA meta-analysis was conducted and showed that the LAP index pooled sensitivity and specificity for screening of NAFLD were 94% (CI95: 72%–99%, I2 = 99%, P < 0.001) and 85% (CI95: 62%–96%, I2 = 99%, P < 0.001), respectively. Conclusion The LAP Index is an inexpensive, sensitive, and specific method to evaluate NAFLD and may be valuable for NAFLD screening.
显示更多 [+] 显示较少 [-]